Log In
BCIQ
Print this Print this
 

Oral MGB-BP-3

  Manage Alerts
Collapse Summary General Information
Company MGB Biopharma Ltd.
DescriptionOral formulation of an antibiotic that binds the minor groove of bacterial DNA
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationClostridium
Indication DetailsTreat Clostridium difficile infection (CDI); Treat Clostridium difficile-associated diarrhea (CDAD)
Regulatory Designation U.S. - Qualified Infectious Disease Program (Treat Clostridium difficile-associated diarrhea (CDAD))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/01/2010

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today